Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCTC-0010 in High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease
NCT03158896Phase 1Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Jul 2018
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MSCTC-0010 in Acute Graft-Versus-Host Disease (aGvHD) (2 cohorts), sponsored by University of Kansas Medical Center. Primary endpoint: Treatment-Related Serious Adverse Events at 45 days. Started Jul 2018; status: completed.
02
Drugs
MSCTC-0010
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03158896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158896.